Serimmune — Department of Health and Human Services SBIR Phase I: NIAID

Description

The proposed project aims to build a diagnostic test for chronic T cruzi infection and Chagas disease that not only improves testing performance but that can be readily integrated with similarly developed tests for most clinically important parasitoses Current assays for Chagas disease and other parasitic infections lack desired levels of specificity and require multiple independent assays and testing formats Consequently testing a single specimen for several different clinically important parasitic diseases becomes cost prohibitive and time consuming delaying disease detection and treatment We propose to address this problem by creating a single all in one diagnostic test able to detect ten or more different clinically important parasitic diseases Importantly the proposed strategy could be expanded to a nearly arbitrary number of infectious diseases without resultant increases in final test cost Towards a multiplexed parasitic disease test we will first create an improved test for Chagas disease that impacts about individuals in the US and million in the Americas To accomplish this we will apply bacterial display peptide libraries next generation sequencing and computational bioinformatics to identify a set of motifs and consensus peptides corresponding to antigenic peptide epitopes that when combined yield optimal sensitivity and specificity values in the discovery set The motif and peptide panels will be validated using an independent specimen set Assay reproducibility and stability will be measured This project may thus lead to clinically useful tests to improve the rates of detection parasitic diseases their resultant complications A majority of individuals with chronic parasitic infections are undiagnosed In particular an estimated individuals in the US are chronically infected with T cruzi the causative agent of Chagas disease Although molecular diagnostics are available to detect Chagas and other parasitoses they lack the ability to be parallelized into a single testing assay that could be deployed broadly to screen at risk populations for these clinically important diseases The proposed project aims to develop the capability to detect tens of different potential parasitic infectious using a single blood test and could be expanded to many other infectious diseases